I'm not convinced shielding the patients is what this is truly about. Probably a few people stand to gain something while tightening ties with their buddies along the way. Curious how the talk ahead will unfold.
I heard the American drug safety agency recently rolled out a green list import warning aimed at blocking risky GLP-1 ingredients from unchecked overseas makers before they reach domestic buyers. The move focuses on shielding people taking blended versions of these meds by adding to the list only those ingredients from spots the agency reviewed and deemed acceptable under tough guidelines that also cover domestic production. Everything else faces holding at entry without inspection.